AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Company profile
Ticker
ABBV, ABBV-MM
Exchange
Website
CEO
Richard Gonzalez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
AbbVie Aviation LLC • AbbVie Biopharmaceuticals LLC • AbbVie Bioresearch Center Inc. • AbbVie Biotech Ventures Inc. • AbbVie Biotherapeutics Inc. • AbbVie Domestic Holdings Inc. • AbbVie Endocrine Inc. • AbbVie Endocrinology Inc. • AbbVie Finance Corporation • AbbVie Finance LLC ...
IRS number
320375147
ABBV stock data
Latest filings (excl ownership)
8-K
AbbVie Reports First-Quarter 2024 Financial Results
26 Apr 24
8-K
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
3 Apr 24
PX14A6G
Letter to shareholders
26 Mar 24
ARS
2023 FY
Annual report to shareholders
18 Mar 24
DEFA14A
Additional proxy soliciting materials
18 Mar 24
DEF 14A
Definitive proxy
18 Mar 24
PRE 14A
Preliminary proxy
4 Mar 24
8-K
Other Events
26 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
FWP
Free writing prospectus
22 Feb 24
Transcripts
ABBV
Earnings call transcript
2024 Q1
26 Apr 24
ABBV
Earnings call transcript
2023 Q4
2 Feb 24
ABBV
Earnings call transcript
2023 Q3
27 Oct 23
ABBV
Earnings call transcript
2023 Q2
27 Jul 23
ABBV
Earnings call transcript
2023 Q1
27 Apr 23
ABBV
Earnings call transcript
2022 Q4
9 Feb 23
ABBV
Earnings call transcript
2022 Q3
28 Oct 22
ABBV
Earnings call transcript
2022 Q2
29 Jul 22
ABBV
Earnings call transcript
2022 Q1
29 Apr 22
ABBV
Earnings call transcript
2021 Q4
2 Feb 22
Latest ownership filings
4
Susan E Quaggin
2 Apr 24
4
Robert J Alpern
2 Apr 24
4
EDWARD J RAPP
2 Apr 24
4
Nicholas Donoghoe
22 Mar 24
144/A
Notice of proposed sale of securities (amended)
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Jeffrey Ryan Stewart
20 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
4
TIMOTHY J. RICHMOND
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
49.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2718 |
Opened positions | 273 |
Closed positions | 515 |
Increased positions | 965 |
Reduced positions | 1180 |
13F shares | Current |
---|---|
Total value | 127.78 tn |
Total shares | 872.48 mm |
Total puts | 4.96 mm |
Total calls | 6.98 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 160.40 mm | $24.86 tn |
STT State Street | 78.20 mm | $12.12 tn |
JPM JPMorgan Chase & Co. | 51.82 mm | $8.03 tn |
Capital International Investors | 44.99 mm | $6.97 tn |
MS Morgan Stanley | 34.05 mm | $5.28 tn |
Capital Research Global Investors | 30.30 mm | $4.70 tn |
Charles Schwab Investment Management | 24.45 mm | $3.77 tn |
BK Bank Of New York Mellon | 22.10 mm | $3.43 tn |
NTRS Northern Trust | 20.94 mm | $3.24 tn |
LGEN Legal & General | 15.21 mm | $2.36 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Edward J Rapp | Stock Equivalent Units Common Stock | Grant | Acquire A | No | No | 182.1 | 212 | 38.61 k | 25,701 |
31 Mar 24 | Susan E Quaggin | Stock Equivalent Units Common Stock | Grant | Acquire A | No | No | 182.1 | 82 | 14.93 k | 147 |
31 Mar 24 | Alpern Robert J | Stock Equivalent Units Common Stock | Grant | Acquire A | No | No | 182.1 | 41 | 7.47 k | 9,408 |
20 Mar 24 | Nicholas Donoghoe | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 176.3 | 21,082 | 3.72 mm | 55,903 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 178.69 | 27,740 | 4.96 mm | 60,941 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 179.03 | 5,099 | 912.87 k | 88,681 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Sell | Dispose S | No | No | 178.85 | 26,110 | 4.67 mm | 93,780 |
18 Mar 24 | Jeffrey Ryan Stewart | Common Stock, $0.01 par value | Option exercise | Acquire M | No | No | 61.36 | 26,110 | 1.60 mm | 119,890 |
18 Mar 24 | Jeffrey Ryan Stewart | Option Common Stock | Option exercise | Dispose M | No | No | 61.36 | 26,110 | 1.60 mm | 0 |
News
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
26 Apr 24
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
26 Apr 24
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
25 Apr 24
AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Worst Pruritus Numerical Rating Scale Of 0 Or 1 At Week 16
25 Apr 24
AbbVie's Options Frenzy: What You Need to Know
23 Apr 24
Press releases
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
25 Apr 24
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
22 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
18 Apr 24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
12 Apr 24